| # | Title | Journal | Year | Citations |
|---|
| 1 | SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 | Journal of Hematology and Oncology | 2020 | 505 |
| 2 | Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants | Nature | 2022 | 146 |
| 3 | Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses | Nature Reviews Immunology | 2023 | 112 |
| 4 | Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages | Signal Transduction and Targeted Therapy | 2022 | 96 |
| 5 | Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma | Emerging Microbes and Infections | 2022 | 42 |
| 6 | AMPK and Akt/mTOR signalling pathways participate in glucose‐mediated regulation of hepatitis B virus replication and cellular autophagy | Cellular Microbiology | 2020 | 36 |
| 7 | Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant | Clinical Microbiology Reviews | 2022 | 35 |
| 8 | Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances | 2020 | 33 |
| 9 | Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives | Computational and Structural Biotechnology Journal | 2020 | 32 |
| 10 | Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41 | Viruses | 2019 | 30 |
| 11 | A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein | Cell Research | 2022 | 27 |
| 12 | Population genomics provides insights into the evolution and adaptation to humans of the waterborne pathogen Mycobacterium kansasii | Nature Communications | 2021 | 20 |
| 13 | Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease | International Journal of Molecular Sciences | 2021 | 19 |
| 14 | Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant | Viruses | 2022 | 15 |
| 15 | Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages | Cell Research | 2022 | 14 |
| 16 | A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein | Cell Discovery | 2022 | 13 |
| 17 | SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors | Emerging Microbes and Infections | 2023 | 13 |
| 18 | Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines | Journal of Medical Virology | 2023 | 12 |
| 19 | The current emergence of monkeypox: The recurrence of another smallpox? | Biosafety and Health | 2022 | 10 |
| 20 | SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors | Journal of Medical Virology | 2023 | 9 |
| 21 | Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis 1 | Emerging Microbes and Infections | 2022 | 6 |
| 22 | Up or down: where comes Omicron? | Cell Research | 2022 | 5 |
| 23 | A System Based on Novel Parainfluenza Virus PIV5-L for Efficient Gene Delivery of B-Lymphoma Cells | Journal of Virology | 2022 | 4 |
| 24 | Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines | Signal Transduction and Targeted Therapy | 2023 | 3 |
| 25 | Characterization of cross‐reactive monoclonal antibodies against SARS‐CoV‐1 and SARS‐CoV‐2: Implication for rational design and development of pan‐sarbecovirus vaccines and neutralizing antibodies | Journal of Medical Virology | 2023 | 1 |
| 26 | Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses | Current Opinion in Virology | 2022 | 0 |
| 27 | Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines | Emerging Microbes and Infections | 2023 | 0 |
